Avlar BioVentures

Avlar BioVentures was a Cambridge, United Kingdom-based venture capital firm founded in 1999 by biotechnology entrepreneur Alan Goodman. See contact routes.

About Avlar BioVentures

Avlar BioVentures was a Cambridge, United Kingdom-based venture capital firm founded in 1999 by biotechnology entrepreneur Alan Goodman and Daniel Roach to finance early-stage biotech companies. The firm’s investment thesis targeted seed and early-stage opportunities in biotechnology and healthcare across the UK and mainland Europe, focusing on therapeutics, diagnostics, medical devices, bioinformatics, and epigenetics. Initial checks ranged from £100,000 to £300,000 to launch companies, with follow-on funding available up to a total of £2 million, and the firm typically acted as an early-stage investor. Notable portfolio companies include Intercytex Group (the fund’s first investment), De Novo Pharmaceuticals, Purely Proteins Limited, CellCentric, and Crescendo Biologics. Avlar managed over €150 million across three funds, including Avlar BioVentures Fund I and Fund II, and completed 27 investments before its latest recorded activity in November 2011. The firm exited its investment in NXVISION and is now considered inactive, with its Fund II having been liquidated.

Avlar BioVentures at a glance

Investor type
Venture Capital

Frequently asked about Avlar BioVentures

What does Avlar BioVentures invest in?
We have not verified a stated sector or stage focus for Avlar BioVentures. The profile lists the organization, location and investors we track alongside them.
How do I contact Avlar BioVentures?
Avlar BioVentures's published profile links (website, LinkedIn or X where available) are listed on the StartupFundraising.com investor profile.
Where is Avlar BioVentures headquartered?
Location details for Avlar BioVentures are listed on their StartupFundraising.com profile when disclosed.

This profile is part of the StartupFundraising firm database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find comparable investors.

Investors similar to Avlar BioVentures (20)

Browse related investor lists (1)

Compare Avlar BioVentures (8)

Investors like Avlar BioVentures · Full investor directory · Investor access · Company funding database

Resources
Join free
Sign Out Dashboard

The Startup Fundraising Platform

Raise funds for your startup

Find the right investors and get real replies — instantly, powered by AI.

  • AI-scored pitch deck
  • Matched investor list
  • Personalized outreach drafts
Join for free

Takes 30 seconds · No credit card · Cancel anytime

See it in action ↓
  • Library
  • Articles
  • Pitch Decks
  • Videos
  • Shorts
  • Profiles
  • Visuals
  • Questions
  • Ask
  • All
  • Seed & Pre-Seed
  • Series A & B
  • Fintech
  • SaaS & Dev Tools
  • Consumer & Social
  • Marketplace & Frontier
  • Mistakes to Avoid
  • Checklist
  • How to Send
  • Design
  • Length
  • Order
  • Storytelling
  • Investor Q&A
  • One-Pager
  • Email Templates
  • Data Room
  • Investor Update
  • Term Sheet
  • SAFE vs Priced
  • Due Diligence
  • Timeline
  • Metrics
  • Valuation
  • Cap Table
  • Pipeline
  • Board
  • Objections
  • References
  • Closing
  • Bridge Round
  • Down Round
  • Secondary Sale
  • Investor Rejection
  • First Meeting
  • Second Meeting
  • Partner Meeting
  • Post-Mortem
  • Update Cadence
  • Angel Round
  • Option Pool Shuffle
  • Fundraise Pause
  • Vetting VCs
  • First 90 Days
  • First Board Meeting
  • Reference Calls
  • NDA Template
  • Bylaws Template
LibraryPitch Deck Examples

Slide-by-slide guide

 

  • Library
  • Articles
  • Pitch Decks
  • Videos
  • Shorts
  • Profiles
  • Visuals
  • Questions
  • Ask
LibraryArticles

•By Alejandro Cremades